High dose 131I-MIBG (metaiodobenzylguanadine) is currently being used to treat patients with malignant pheochromocytomas and paragangliomas. This therapy is available at the University of California, San Francisco (UCSF) under a Phase II protocol that has been approved by three UCSF review boards: The Committee on Human Research, The Comprehensive Cancer Center Protocol Committee, and the Pediatric Clinical Research Center.

Patients are considered for 131I-MIBG therapy only if their malignant tumors are avid for MIBG on diagnostic scans. Over 30 patients have been treated over the last 12 years; the majority of patients have experienced remissions, including several patients with complete remissions. We would like to recruit an additional 20 patients over the next 5 years.

For more information about high-dose 131I-MIBG therapy at UCSF, please contact:

Paul A. Fitzgerald, M.D.
Clinical Professor of Medicine
University of California, San Francisco
350 Parnassus Avenue, Suite 710
San Francisco, CA 94117
Email: paulf@itsa.ucsf.edu
Phone: 415-665-1136

Visit University of California's Website.